Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224100 | 1.00 | NLRP3 (0.46) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL23207368 | 0.85 | CYP1A2 (0.50) | KMT2AAKR1B1TSHRMEN1HIF1A | |
| SCHEMBL28915742 | 0.85 | CYP1A2 (0.50) | KMT2AAKR1B1TSHRMEN1HIF1A | |
| SCHEMBL28019768 | 0.83 | KMT2A (0.46) | KMT2ATSHRLMNAMEN1 | |
| SCHEMBL22113081 | 0.81 | NLRP3 (0.45) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL2586006 | 0.81 | NLRP3 (0.45) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL2502292 | 0.81 | NLRP3 (0.45) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL29478100 | 0.81 | NLRP3 (0.45) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL27420544 | 0.81 | NLRP3 (0.45) | NLRP3KMT2AAKR1B1TSHRLMNA | |
| SCHEMBL16812596 | 0.81 | KMT2A (0.44) | KMT2ACYP2D6MIFIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPUETICS INCORPORATED | 2022-03-03 | — | — | US | disclosed |
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPUETICS INCORPORATED | 2022-03-03 | — | — | US | disclosed |
| WO-2020123994-A1 | 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064170-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CYP2C19, CYP2D6, CYP2C8 | NLRP3 3520/4885KMT2A 4413/4885AKR1B1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.